ArticleClinical rheumatology2026
Maternal and fetal risks in familial mediterranean fever: focus on adverse pregnancy outcomes.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate fetal and maternal pregnancy outcomes in pregnant women with familial Mediterranean fever (FMF).
methodsA total of 89 FMF patients with a history of at least one pregnancy were included in this retrospective study. FMF characteristics, obstetric history, FMF attacks during pregnancy, treatments, fetal and maternal complications and adverse pregnancy outcomes (APOs) were recorded.
resultsOverall, 47.2% of patients had FMF attacks during pregnancy (22.5%, 19.1% and 15.7% at the first, second and third trimesters, respectively). APOs were identified in 28.1% (n = 25) of pregnancies, while 29.2% of newborns were admitted to the neonatal intensive care unit (NICU). Majority (95.5%) of patients received FMF treatment during pregnancy including colchicine in 74.2% of patients. Presence of FMF attacks at the second (OR: 15.5, 95% CI: 1.43-167.0, p = 0.024) and third (OR: 20.6, 95% CI: 1.53-278.0, p = 0.023) trimesters was significantly associated with the development of APOs. Presence of FMF attacks during pregnancy (OR 4.63, 95% CI 1.54-13.96, p = 0.006) and higher number of caesarean sections (OR 1.90, 95% CI 1.10-3.29, p = 0.021) were independent predictors of NICU admission.
conclusionIn conclusion, presence of FMF attacks during pregnancy was associated with the increased risk of APOs and NICU admissions in pregnancies with FMF, alongside their potential association with miscarriage and preterm delivery. Effective control of active disease with close follow-up, prophylaxis and treatment and having a planned pregnancy after achieving disease remission seem to be of critical importance in improving pregnancy outcomes in patients with FMF. Key Points • This study provides data on adverse pregnancy outcomes (APOs) in pregnant women with familial Mediterranean fever (FMF), across demographic, obstetric and clinical characteristics • APOs and need for neonatal intensive care unit (NICU) admission were noted in one third of pregnancies with FMF, emphasizing that fetal complications remain a significant concern in pregnancies with FMF. • FMF attacks occurred in almost half of pregnancies, while having an FMF attack during pregnancy was significantly associated with the increased risk of both APOs and NICU admissions. • Effective control of active disease with close follow-up, prophylaxis and treatment and having a planned pregnancy after achieving disease remission seem to be of critical importance in improving pregnancy outcomes in patients with FMF.
Indexed as
Identifiers
41266826What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.